BVAXF · BioVaxys Technology Corp.
Market Cap
$3.72M
Shares
40.65M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.10
Open$0.07
Day$0.07–0.10
52W close$0.03–0.22
Avg vol 30d23K
Short int14K · 0.0% float · 1.0d
Short vol9%
DataJan 2020–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-47.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
−4%
below
RSI (14)
51
neutral
MACD trend
Positive
52-week position
35%
mid-range
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+25%
trailing
YTD return
−42%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.03% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
28
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
380%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
28.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
35%
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.03% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 35%
Range high $0
vs 200-day avg -17%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BVAXF
this stock
BioVaxys Technology Corp.
|
$3.72M | -41.8% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.9% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +2.3% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +18.4% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.0%
- Net QoQ
- +500 sh
- Top holder
- Strategic Asset Managemen…
Held
Float
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BVAXF | -29.2% | +25.0% | +24.8% | +41.3% | -41.8% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -29.8% | +25.8% | +6.6% | +41.8% | -53.6% |